Biology:Influenzavirus C

From HandWiki

Orthomyxoviridae
Virus classification
Group:
Group V ((−)ssRNA)
Family:
Orthomyxoviridae
Genus:
Influenzavirus C
Genera

Influenza virus C is a genus in the virus family Orthomyxoviridae, which includes the viruses that cause influenza.

The species in this genus is called Influenza C virus. Influenza C viruses are known to infect humans and pigs.[1]

Flu due to the Type C species is rare compared to Types A or B, but can be severe and can cause local epidemics. Type C has 7 RNA segments and encodes 9 proteins, while Types A and B have 8 RNA segments and encode at least 10 proteins.

Influenza C virus

Influenza viruses are members of the family Orthomyxoviridae.[2] Influenza viruses A, B, C, and D represent the four antigenic types of influenza viruses.[3] Of the four antigenic types, influenza virus A is the most severe, influenza virus B is less severe but can still cause outbreaks, and influenza virus C is usually only associated with minor symptoms.[4]

Influenza virus A can infect a variety of animals as well as humans, and its natural host or reservoir is birds, whereas influenza viruses B, C, and D do not have animal reservoirs.[4][5][6] Influenza virus C is not as easily isolated so less information is known of this type, but studies show that it occurs worldwide.[7] Influenza virus C currently has 6 lineages, which were estimated to have emerged around 1896 AD.[6]

This virus may be spread from person to person through respiratory droplets or by fomites (non-living material) due to its ability to survive on surfaces for short durations.[4] Influenza viruses have a relatively short incubation period (lapse of time from exposure to pathogen to the appearance of symptoms) of 18–72 hours and infect the epithelial cells of the respiratory tract.[4] Influenza virus C tends to cause mild upper respiratory infections.[8] Cold-like symptoms are associated with the virus including fever (38-40ᵒC), dry cough, rhinorrhea (nasal discharge), headache, muscle pain, and achiness.[4][9] The virus may lead to more severe infections such as bronchitis and pneumonia.[8]

After an individual becomes infected, the immune system develops antibodies against that infectious agent. This is the body’s main source of protection.[4] Most children between five and ten years old have already produced antibodies for influenza virus C.[9] As with all influenza viruses, type C affects individuals of all ages, but is most severe in young children, the elderly and individuals with underlying health problems.[4][10] Young children have less prior exposure and have not developed the antibodies and the elderly have less effective immune systems.[4] Influenza virus infections have one of the highest preventable mortalities in many countries of the world.[10]

Structure and Variation

Influenza viruses, like all viruses in the family Orthomyxoviridae, are enveloped RNA viruses with single stranded genomes.[2] The antigens, matrix protein (M1) and nucleoprotein (NP), are used to determine if an influenza virus is type A, B, C, or D.[4] The M1 protein is required for virus assembly and NP functions in transcription and replication.[11][12] These viruses also contain proteins on the surface of the cell membrane called glycoproteins. Type A and B have two glycoproteins: hemagglutinin (HA) and neuraminidase (NA). Types C and D have only one glycoprotein: hemagglutinin-esterase fusion (HEF).[4][13][6] These glycoproteins allow for attachment and fusion of viral and cellular membranes. Fusion of these membranes allows the viral proteins and genome to be released into the host cell, which then causes the infection.[14] Types C and D are the only influenza viruses to express the enzyme esterase. This enzyme is similar to the enzyme neuraminidase produced by Types A and B in that they both function in destroying the host cell receptors.[8] Glycoproteins may undergo mutations (antigenic drift) or reassortment in which a new HA or NA is produced (antigenic shift). Influenza virus C is only capable of antigenic drift whereas Type A undergoes antigenic shift, as well. When either of these processes occur, the antibodies formed by the immune system no longer protect against these altered glycoproteins. Because of this, viruses continually cause infections.[4]

Identification

Influenza virus C is different from Types A and B in its growth requirements. Because of this, it is not isolated and identified as frequently. Diagnosis is by virus isolation, serology, and other tests.[9] Hemagglutination inhibition (HI) is one method of serology that detects antibodies for diagnostic purposes.[7] Western blot (immunoblot assay) and enzyme-linked immunosorbent assay (ELISA) are two other methods used to detect proteins (or antigens) in serum. In each of these techniques, the antibodies for the protein of interest are added and the presence of the specific protein is indicated by a color change.[15] ELISA was shown to have higher sensitivity to the HEF than the HI test.[5] Because only Influenza viruses C and D produce esterase, In Situ Esterase Assays provide a quick and inexpensive method of detecting just Types C and D.[8] If more individuals were tested for Influenza virus C as well as the other three types, infections not previously associated with Type C may be recognized.[8]

Vaccination

Effective and safe vaccines have been developed for influenza viruses.[16] The Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO) are constantly surveying the wild population of viruses. In doing this, they are able to predict which virus strains might cause the most harm each year during flu season. The strains expected to be most harmful are put into the vaccine for that year's flu vaccine. These vaccines are more commonly known as “flu shots”.[4]

Vaccines can use living strains that have been made less harmful or inactive strains. Both forms work by exposing the body to the viral strains within the vaccine. As a result, the immune system develops antibodies providing protection from these strains.[3] Studies show that the vaccines containing less harmful forms of living strains are more effective in providing immunity.[17] It is recommended that all individuals be vaccinated each year, especially health care providers and individuals with chronic illness, in order to prevent infection from influenza viruses.[10][17] Influenza virus vaccines have beneficial implications to an individual’s health.[17]

Because influenza virus A has an animal reservoir that contains all the known subtypes and can undergo antigenic shift, this type of influenza virus is capable of producing pandemics.[5] Influenza viruses A and B also cause seasonal epidemics every year due to their ability to antigenic shift.[3] Influenza virus C does not have this capability and it is not thought to be a significant concern for human health.[5] Therefore, there are no vaccinations against influenza virus C.[4]

References

  1. ↑ Guo Y.; Jin F.; Wang P.; Wang M.; Zhu J.M. (1983). "Isolation of Influenza C Virus from Pigs and Experimental Infection of Pigs with Influenza C Virus". Journal of General Virology 64: 177–82. doi:10.1099/0022-1317-64-1-177. PMID 6296296. 
  2. ↑ 2.0 2.1 Pattison; McMullin; Bradbury; Alexander (2008). Poultry Diseases (6th ed.). Elsevier. pp. 317. ISBN 978-0-7020-28625. 
  3. ↑ 3.0 3.1 3.2 “Seasonal Influenza (Flu)” Centers for Disease Control and Prevention. March 22, 2012. https://www.cdc.gov/flu/about/viruses/types.htm
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 Margaret Hunt. “Microbiology and Immunology On-line” University of South Carolina School of Medicine. 2009. http://pathmicro.med.sc.edu/mhunt/flu.htm
  5. ↑ 5.0 5.1 5.2 5.3 World Health Organization (2006). "Review of latest available evidence on potential transmission of avian influenza (H5H1) through water and sewage and ways to reduce the risks to human health" (PDF). http://apps.who.int/iris/bitstream/10665/204275/1/WHO_SDE_WSH_06.1_eng.pdf. 
  6. ↑ 6.0 6.1 6.2 Shuo Su; Xinliang Fu; Gairu Li; Fiona Kerlin; Michael Veit (25 August 2017). "Novel Influenza D virus: Epidemiology, pathology, evolution and biological characteristics". Virulence 8 (8): 1580–1591. doi:10.1080/21505594.2017.1365216. PMID 28812422. PMC 5810478. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810478/. 
  7. ↑ 7.0 7.1 "Sero-epidemiological survey of influenza C virus infection in Spain". Eur. J. Epidemiol. 10 (1): 91–94. 1994. PMID 7957798. 
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Wagaman, Spence & O'Callaghan 1989
  9. ↑ 9.0 9.1 9.2 "Clinical features of influenza C virus infection in children". J. Infect. Dis. 193 (9): 1229–35. 2006. doi:10.1086/502973. PMID 16586359. https://academic.oup.com/jid/article-lookup/doi/10.1086/502973. 
  10. ↑ 10.0 10.1 10.2 "Attitudes and behavior of health care personnel regarding influenza vaccination". Eur. J. Epidemiol. 10 (1): 63–68. 1994. PMID 7957793. 
  11. ↑ "Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein". J. Virol. 74 (18): 8709–19. 2000. PMID 10954572. PMC 116382. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=10954572. 
  12. ↑ "The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication". J. Gen. Virol. 83 (Pt 4): 723–34. 2002. doi:10.1099/0022-1317-83-4-723. PMID 11907320. http://jgv.microbiologyresearch.org/pubmed/content/journal/jgv/10.1099/0022-1317-83-4-723. 
  13. ↑ "A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF". J. Virol. 82 (13): 6419–26. 2008. doi:10.1128/JVI.00514-08. PMID 18448539. PMC 2447078. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=18448539. 
  14. ↑ "Structural basis for membrane fusion by enveloped viruses". Mol. Membr. Biol. 16 (1): 3–9. 1999. PMID 10332732. 
  15. ↑ Nelson, DL; Cox, MM (2013). Principles of Biochemistry (6th ed.). pp. 179. ISBN 978-1-4292-3414-6. 
  16. ↑ "The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children". N. Engl. J. Med. 338 (20): 1405–12. 1998. doi:10.1056/NEJM199805143382002. PMID 9580647. http://www.nejm.org/doi/abs/10.1056/NEJM199805143382002. 
  17. ↑ 17.0 17.1 17.2 "Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children". Philos. Trans. R. Soc. Lond. B Biol. Sci. 356 (1416): 1947–51. 2001. doi:10.1098/rstb.2001.0982. PMID 11779396. PMC 1088573. http://rstb.royalsocietypublishing.org/cgi/pmidlookup?view=long&pmid=11779396. 

Further reading

External links

Wikidata ☰ Q17330294 entry

de:Influenzavirus#Influenza-C-Subtypen




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Influenzavirus_C&oldid=106731"